Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women
Kristyn A Bates, Hamid R Sohrabi, Stephanie R Rainey-Smith, Michael Weinborn, Romola S Bucks, Mark Rodrigues, John Beilby, Matthew Howard, Kevin Taddei, Georgia Martins, Athena Paton, Tejal Shah, Satvinder S Dhaliwal, Jonathan K Foster, Ian J Martins, Nicola T Lautenschlager, Frank L Mastaglia, Samuel E Gandy, Ralph N Martins
International Journal of Neuroscience | TAYLOR & FRANCIS LTD | Published : 2017
Awarded by National Health and Medical Research Council of Australia
Awarded by NATIONAL INSTITUTE ON AGING
Ralph N. Martins is the founder, and owns stocks of Alzhyme. Hamid R. Sohrabi has previously received payments from Wyeth and Pfizer, and receives remuneration for ongoing work undertaken as part of the Takeda TOMMORROW Study Clinical Trial. Jonathan K. Foster has previously received payment from Pfizer. Samuel Gandy is a consultant for, owns stock/options in, and/or has received lecture fees from Amicus, Diagenic, Epix, Smart Pharma and Wyeth/Elan. Samuel Gandy is also a member of the data safety monitoring board for the Alzheimer Immunotherapy Alliance and holds a grant from Amicus Pharmaceuticals. There are no other actual or potential conflicts of interest. Kristyn A. Bates is supported by grants funded by the Raine Medical Research Foundation (Western Australia) and the Neurotrauma Research Program (Western Australia). Hamid R. Sohrabi is supported by grants and funds from Edith Cowan University, Cooperative Research Centre for Mental Health-Australia, the Neurotrauma Research Program and the McCusker Charitable Foundation (Western Australia). This study was supported by the National Health and Medical Research Council of Australia (Grant Number: 324100 awarded to Ralph N. Martins), the McCusker Alzheimer's Research Foundation Inc., Hollywood Private Hospital, and the McCusker Charitable Foundation.